Gland Pharma is implementing a two-pronged strategy in GLP-1 opportunity. (Photo Source: Gland Pharma website). Gland Pharma delivered in-line revenue in Q2 FY26. However, Ebitda/PAT came in below brokerage's expectations by 9%/11%. A lower than-expected share of milestone income and lower tech transfer/contract manufacturing organisation business in rest of world markets impacted Q2 FY26 performance.

To continue reading this story You must be an existing Premium User Already a Premium User? Sign In

See Full Page